High‐Dose Hepatitis B Vaccine in Patients Waiting for Lung Transplantation

Hayney, Mary S.; Welter, Deborah L.; Reynolds, Ann Marie; Francois, Mary L.; Love, Robert B.

doi:10.1592/phco.23.5.555.32194

Cited by 20 publications

(19 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with the immune response after immunization before transplantation, the efficacy of standard HBV vaccination is reduced when the vaccine is administered after transplant (with response rates of 5% to 15%) (92,176,(177)(178)(179). Alternative vaccination strategies have been studied.…”

Section: Hbvmentioning

confidence: 99%

Viral Infection in the Renal Transplant Recipient

Kotton

Fishman²

2005

Journal of the American Society of Nephrology

197

181

View full text Add to dashboard Cite

Viruses are among the most common causes of opportunistic infection after transplantation and the most important. The risk for viral infection is a function of the specific virus encountered, the intensity of immune suppression used to prevent graft rejection, and other host factors governing susceptibility. Viral infection, both symptomatic and asymptomatic, causes the "direct effects" of invasive disease and "indirect effects," including immune suppression predisposing to other opportunistic infections and oncogenesis. Rapid and sensitive microbiologic assays for many of the common viruses after transplantation have replaced, for the most part, serologic testing and in vitro cultures for the diagnosis of infection. Furthermore, quantitative molecular tests allow the individualization of antiviral therapies for prevention and treatment of infection. This advance is most prominent in the management of cytomegalovirus, Epstein-Barr, hepatitis B, and hepatitis C viruses. Diagnostic advances have not been accompanied by the development of specific and nontoxic anti-viral agents or effective antiviral vaccines. Vaccines, where available, should be given to patients as early as possible and well in advance of transplantation to optimize the immune response. Studies of viral latency, reactivation, and the cellular effects of viral infection will provide clues for future strategies in prevention and treatment of viral infections.

show abstract

Section: Hbvmentioning

confidence: 99%

Viral Infection in the Renal Transplant Recipient

Kotton

Fishman²

2005

Journal of the American Society of Nephrology

197

181

View full text Add to dashboard Cite

show abstract

“…6,7 We and others have reported compromised responses to hepatitis B vaccine in patients with chronic health conditions, including those with serious lung disease who are waiting for lung transplantation. 2,[8][9][10][11][12][13][14] Because immunosuppression targets T lymphocytes and patients awaiting lung transplantation have difficulty mounting antibody responses to hepatitis B vaccine, 8 we hypothesized that lung transplant recipients and patients awaiting lung transplantation would have a lower DTH response to hepatitis B surface antigen (HBsAg) than that of healthy individuals.…”

mentioning

confidence: 99%

T‐Cell Responses to Hepatitis B Surface Antigen in Lung Transplant Recipients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…(33)(34)(35)(36)(37). Profilaksi: HBV'ye karşı immünitesi olmayan hastalar transplantasyon öncesi aşılanmalıdır (37)(38)(39)(40).…”

Section: Hemodiyaliz Hastalarında Kronik Hepatit B Tedavisiunclassified

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Mıstık¹,

Aydın²,

Aksoy³

et al. 2015

Klimik Dergisi

View full text Add to dashboard Cite

ÖzetTürk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu, özel konaklarda ve özel durumlarda kronik hepatit yönetimine ilişkin bir uzlaşı raporu hazırlamak üzere bir toplantı düzenlemiştir. Raporda konuyla ilgili literatür ve uluslararası kılavuzlar, hepatit B virusu (HBV) için sırasıyla kompanse ve dekompanse sirozlu hastalarda kronik hepatit B (KHB) tedavisi, karaciğer nakli sonrası HBV infeksiyonunun nüks etmesinden korunma ve nüks gelişen hastalarda tedavi, fülminan hepatit B tedavisi, hemodiyaliz hastalarında KHB teda- AbstractStudy Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis in special hosts and special situations. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as therapy of chronic hepatitis B (CHB) in patients with compensated and decompensated cirrhosis, prevention and therapy of recurrent hepatitis B after liver transplantation, management of fulminant

show abstract

High‐Dose Hepatitis B Vaccine in Patients Waiting for Lung Transplantation

Abstract: The high-dose hepatitis B vaccine series produced a protective immune response in lung transplant recipients; however, the response was suboptimal, and alternative immunization strategies should be studied.

Cited by 20 publications

References 40 publications

Viral Infection in the Renal Transplant Recipient

Viral Infection in the Renal Transplant Recipient

T‐Cell Responses to Hepatitis B Surface Antigen in Lung Transplant Recipients

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Contact Info

Product

Resources

About